Drug Profile
Oxylanthanum carbonate- Assertio Therapeutics/Unicycive Therapeutics
Alternative Names: Lanthanum dioxycarbonate; OLC; RenaZorb; RZB-014; SPI-014 - Assertio TherapeuticsLatest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Altair Nanotechnologies
- Developer Assertio Therapeutics
- Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 18 Dec 2023 Unicycive Therapeutics plans to submit NDA to the US FDA for Oxylanthanum Carbonate in 2024
- 18 Dec 2023 Unicycive Therapeutics initiates a phase I bioequivalence trial for hyperphosphatasemia in the US (Prior to December 2023)
- 15 Dec 2023 Phase-II clinical trials in Hyperphosphataemia (Treatment-experienced) in USA (PO) (NCT06218290)